A defect in indoleamine 2,3-dioxygenase 1 (IDO1), which is responsible for immunoregulatory tryptophan catabolism, impairs development of immune tolerance to autoantigens in NOD mice, a model for human autoimmune type 1 diabetes (T1D). Whether IDO1 function is also defective in T1D is still unknown. We investigated IDO1 function in sera and peripheral blood mononuclear cells (PBMCs) from children with T1D and matched controls. These children were further included in a discovery study to identify SNPs in IDO1 that might modify the risk of T1D. T1D in children was characterized by a remarkable defect in IDO1 function. A common haplotype, associated with dysfunctional IDO1, increased the risk of developing T1D in the discovery and also confirmation studies. In T1D patients sharing such a common IDO1 haplotype, incubation of PBMCs in vitro with tocilizumab (TCZ) - an IL-6 receptor blocker - would, however, rescue IDO1 activity. In an experimental setting with diabetic NOD mice, TCZ was found to restore normoglycemia via IDO1-dependent mechanisms. Thus, functional SNPs of IDO1 are associated with defective tryptophan catabolism in human T1D, and maneuvers aimed at restoring IDO1 function would be therapeutically effective in at least a subgroup of T1D pediatric patients.

Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1 in juvenile diabetes

Orabona, Ciriana;Mondanelli, Giada;Pallotta, Maria T;Carvalho, Agostinho;Albini, Elisa;Fallarino, Francesca;Vacca, Carmine;Volpi, Claudia;Belladonna, Maria L;Ceccarini, Giulia;Esposito, Susanna Mr;Scattoni, Raffaella;Verrotti, Alberto;Ferretti, Alessandra;Cappa, Marco;Bianchi, Roberta;Matino, Davide;Iacono, Alberta;Puccetti, Matteo;Cunha, Cristina;Antognelli, Cinzia;Talesa, Vincenzo N;Romani, Luigina;Puccetti, Paolo;Grohmann, Ursula
2018

Abstract

A defect in indoleamine 2,3-dioxygenase 1 (IDO1), which is responsible for immunoregulatory tryptophan catabolism, impairs development of immune tolerance to autoantigens in NOD mice, a model for human autoimmune type 1 diabetes (T1D). Whether IDO1 function is also defective in T1D is still unknown. We investigated IDO1 function in sera and peripheral blood mononuclear cells (PBMCs) from children with T1D and matched controls. These children were further included in a discovery study to identify SNPs in IDO1 that might modify the risk of T1D. T1D in children was characterized by a remarkable defect in IDO1 function. A common haplotype, associated with dysfunctional IDO1, increased the risk of developing T1D in the discovery and also confirmation studies. In T1D patients sharing such a common IDO1 haplotype, incubation of PBMCs in vitro with tocilizumab (TCZ) - an IL-6 receptor blocker - would, however, rescue IDO1 activity. In an experimental setting with diabetic NOD mice, TCZ was found to restore normoglycemia via IDO1-dependent mechanisms. Thus, functional SNPs of IDO1 are associated with defective tryptophan catabolism in human T1D, and maneuvers aimed at restoring IDO1 function would be therapeutically effective in at least a subgroup of T1D pediatric patients.
2018
File in questo prodotto:
File Dimensione Formato  
2018 Orabona jci.insight.96244.v1.pdf

accesso aperto

Descrizione: Article full text
Tipologia di allegato: PDF-editoriale
Licenza: Creative commons
Dimensione 2.44 MB
Formato Adobe PDF
2.44 MB Adobe PDF Visualizza/Apri
2018 Orabona suppl data jci.insight.96244.v1.pdf

accesso aperto

Descrizione: Supplementary data
Tipologia di allegato: Altro materiale
Licenza: Creative commons
Dimensione 1.08 MB
Formato Adobe PDF
1.08 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/1429322
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 45
social impact